Skip to main content
BMJ Open logoLink to BMJ Open
. 2024 Jun 27;14(6):e084582. doi: 10.1136/bmjopen-2024-084582

Cross-sectional study to investigate the seroprevalence and risk factors of Toxoplasma gondii among women attending the antenatal clinic in Namwala, Zambia

Victor Daka 1,2,, Moses Mukosha 3, Sharon D Zimba 4, Andrew M Phiri 1
PMCID: PMC11328639  PMID: 38950992

Abstract

Abstract

Background

Toxoplasmosis is a zoonotic parasitic disease caused by Toxoplasma gondii (T. gondii). It has a wide host range and is capable of vertical transmission in pregnant women, which may lead to undesirable pregnancy outcomes such as congenital malformations, miscarriage, premature birth and stillbirth. This study investigated the seroprevalence of T. gondii infection among pregnant women attending the antenatal clinic at Namwala District Hospital in Southern Zambia.

Methods

This was a cross-sectional study where blood was collected, and the serum was tested for Toxoplasma IgG and IgM. A questionnaire was administered to participants on demographic characteristics and risk factors. Data were entered in Microsoft Excel and exported to STATA version 14 for analysis.

Results

A total of 401 women were enrolled in the study from 3 March to 5 August 2021. The seroprevalence of Toxoplasma IgG was 4.2% (n=17), while the seroprevalence of Toxoplasma IgM was 0.7% (n=3). The median age was 27 (IQR: 24–30) years, and a larger proportion had primary-level education (n=223, 55.6%). The majority (81.6%) of the women were married. None of the risk factors investigated in this study were significant for T. gondii infection.

Conclusion

There was a low seroprevalence of T. gondii infection among pregnant women in the Namwala district of Southern Province, Zambia, and regular screening may not be warranted in this population. Continued research on toxoplasmosis is recommended to understand its epidemiology across Zambia.

Keywords: pregnant women, parasitology, microbiology


STRENGTHS AND LIMITATIONS OF THIS STUDY.

  • The study design and population allow the investigation of toxoplasmosis in pregnant women who have the potential of congenitally infecting their unborn children with a possibility of serious clinical implications.

  • The selection of a rural population in Zambia allows the understanding of potential drivers of Toxoplasma exposure in a rural setting not previously investigated.

  • There is a potential pitfall of this study in extrapolating the findings to other populations at it was done at a single facility, but these findings will be key in designing context-specific interventions for toxoplasmosis.

  • Risk factor analysis could not be performed due to the relatively low seroprevelance of Toxoplasma antibodies in this population.

Introduction

Toxoplasmosis is a zoonotic disease caused by the obligate intracellular protozoan parasite Toxoplasma gondii.1 It is estimated to have infected approximately one-third to one-half of the world’s population.2 3 Humans and other warm-blooded animals are intermediate hosts, while the definitive hosts are felids.4 It has a global distribution with prevalence rates ranging from lower than 10% to over 90%.5 The global average seroprevalence of latent toxoplasmosis, a condition where a previously infected person is asymptomatic, was estimated to be 33.8%, with the highest seroprevalence in South America at 56.2%.6

Humans and animals can become infected by ingesting undercooked meat contaminated with T. gondii tissue cysts, direct infection through drinking water and ingesting food contaminated with T. gondii oocysts and congenital transmission from an infected mother to the fetus during pregnancy.7 8 Other transmission routes have been suggested, including drinking contaminated milk and blood transmission.9

Toxoplasmosis is of clinical significance in immunocompromised individuals and pregnant women. Although the infection is generally asymptomatic in individuals with a competent immune system, it can cause undesirable disease sequelae in immunocompromised individuals, such as meningoencephalitis with eye and central nervous system involvement.10 Vertical transmission of T. gondii to the unborn baby in pregnant women, a condition referred to as congenital toxoplasmosis (CT), can result in miscarriages, premature birth, congenital malformation and stillbirths, with the severity of the undesirable birth outcomes decreasing with increased gestational age.11 The disease may present with clinical complications at birth or later in life, which may include miscarriages, stillbirths and congenital diseases such as neurocognitive deficits and chorioretinitis.12 The incidence of CT has been reported in France (2.9/10 000 live births),13 Netherlands (8.1/10 000 live births) and the USA (0.2/10 000 live births).14

Treatment with sulphadoxine pyrimethamine against malaria in pregnant women has also been found to have protective effects against the undesirable consequences of T. gondii infection.15 The current management package for pregnant women in Zambia does not include routine screening for toxoplasmosis, as laboratory testing is restricted to HIV, syphilis, haemoglobin and urinalysis.16 This could be because there is a lack of compelling evidence to inform policy on the need to screen for toxoplasmosis, as there is a paucity of studies in Zambia on the seroprevalence and impact of toxoplasmosis in pregnant women. To our knowledge, only one previous study investigated toxoplasmosis in pregnant women at a large referral hospital in Lusaka, Zambia, and reported a seroprevalence of Toxoplasma IgG of 5.9% and an absence of Toxoplasma IgM antibodies.17 This study was carried out in an urban community with a different social ecological environment and possible transmission routes. The lack of extensive studies illustrates the need for more research into the disease to guide policy. There has been an increased interest in toxoplasmosis in rural areas where there is extensive livestock breeding. This provides a risk of Toxoplasma oocyst contamination to the animals and further to humans.17 18 Here, we carried out a study in the rural district of Namwala in Southern Zambia among pregnant women attending the antenatal clinic at Namwala District Hospital.

Materials and methods

Study design, area and period

This was a cross-sectional study conducted at Namwala District Hospital in Southern Province, Zambia (figure 1). Namwala covers an expanse of land approximately 10 000 square kilometres and lies between latitudes 15 and 17°S and longitudes 25 and 27°E.19 It is a rural area whose population is largely composed of pastoral farmers who share common ecological environments with animals, as livestock rearing is the main economic activity in the district.20 Namwala district hospital is a level 1 hospital, which is the largest referral health facility in the district supporting a catchment area that includes rural health centres including Belina, Kalundu, Chikwata, Location and Maunga. The target population was pregnant women attending the antenatal clinic at Namwala District Hospital from 3 March to 5 August 2021

Figure 1. Map of Namwala District in Southern Province, Zambia.

Figure 1

Study aims and population

The aim of this study was to determine the seroprevalence of toxoplasmosis and its risk factors in pregnant women attending Namwala District Hospital. A total of 462 pregnant women were approached to participate in the study, with 401 who finally enrolled, giving a response rate of 86.8%. Pregnant women who presented with clinical conditions requiring urgent attention and those who refused to give consent were excluded from the study.

Sample size and sampling technique

To estimate the required sample size for the seroprevalence study and risk factors, we used the sample size calculation for cross-sectional studies.21 We employed a conservative prevalence of 50% due to the absence of Toxoplasma seroprevalence data with the only previous study in Zambia conducted in a geographically dissimilar area.16 Considering a finite population of 2400 women attending the antenatal clinic at Namwala District Hospital over the study period, a 20% nonresponse and a precision of 5%, we estimated a minimum sample size of 398 participants.

Pregnant women who met the inclusion criteria were approached, and informed consent was obtained. Approximately 100 women attended the Namwala antenatal clinic weekly. Those who consented were then enrolled using a systematic random sampling approach selecting every fourth participant.

Questionnaire and study measures

Questionnaire administration was conducted by a trained interviewer. The questionnaire had two parts with questions adapted from previous studies.616 22,24 The first part of the questionnaire (Section A) had questions on demographics (10 questions), and the second part (Section B) consisted of questions on risk factors for toxoplasmosis, which were adapted from studies conducted in similar settings (eight questions). We performed face validation by distributing the questionnaire to experts in the Public Health Department at the Copperbelt University, School of Medicine. The questionnaire was pretested on 30 women at the Chipulukusu clinic in Ndola, obtaining a Cronbach’s alpha of 0.76, which indicated good reliability according to methods described previously.25 The results from the pre-test were used to optimise the questionnaire but were removed from the final analysis.

Blood collection, transportation and analysis

Approximately 4 mL of venous blood was collected in plain containers by a laboratory technologist using aseptic methods. The sample collection was conducted from the Mother and Child Health section of the Hospital and immediately transported to the Namwala District Hospital Laboratory for processing. After clotting, the blood was centrifuged at 3000 revolutions per minute for 3 min, and the serum was aliquoted and stored in cryovials at −20°C. All collected samples were transported monthly under cold storage using SnoMaster mobile cooler boxes (SnoMaster, Johannesburg, South Africa) to the Tropical Diseases Research Centre (TDRC) laboratory in Ndola, Zambia, for analysis. The samples were analysed for Toxoplasma IgM and IgG using the immunochromatographic lateral flow test OnSite Toxo IgM/IgG Combo Rapid Test (CTK Biotech Inc, CA, USA) according to the manufacturer’s instructions. This assay has been evaluated against traditional enzyme-linked immunosorbent assay (ELISA) methods and found to give optimal results in the diagnosis of T. gondii antibodies.26 27 Briefly, approximately 10 µL of the serum was added to the sample well of the immunochromatographic test cassette. Two drops of sample diluent were then added to the diluent well and incubated on a horizontal surface for 12 min. All results were read and interpreted after the incubation period. A valid positive result was interpreted as the presence of a red line on the IgG or IgM in the presence of a C (control) line. The absence of either the IgG or IgM line in the presence of a C line represented a negative result. All Toxoplasma-seropositive mothers were referred to the attending physician in the antenatal clinic for further management.

Statistical analysis

Data from questionnaires were entered in Microsoft Excel (Microsoft, Redmond, WA, USA) for cleaning (online supplemental file 1) and then transferred to STATA version 14 (Stata Corp, College Station, Texas, USA) for statistical analysis. We reported the frequency (%) for categorical variables and the median (IQR) for continuous variables. Univariate analysis was done to select covariates to include in the multivariate level at p<0.25. All selected covariates were then included in the multivariate logistic regression model using the enter method. The regression model was not statistically significant (χ2=14.033, p=0.121). The regression model explained 10.8% (Nagelkerke R2) of the variance in toxoplasmosis among pregnant women and correctly classified 95.3% of the cases. This implies that the combined effect of environmental factors (keeping cats, cleaning cat litter, contact with soil, boiling water) and human host factors (education, parity) were insufficient for susceptible pregnant women to develop toxoplasmosis in this study.

Ethical approval and consent to participate

Ethical approval for the study protocol (online supplemental file 2) was obtained from the TDRC Research Ethics committee (Institutional Review Board Number 00002911) (online supplemental file 3). Authority to conduct the study was granted by the National Health Research Authority. Permission to conduct the study at Namwala District Hospital was obtained from the office of the Provincial Health Director for Southern Province and District Health Director for Namwala district. Written informed consent was obtained from all participants who were enrolled in the study after informing them about the study, the risks being minimal pain and discomfort at the site of needle puncture during blood collection and their right to withdraw at any given time during the study. All data for the study were restricted to the investigators, and no participant identifiers were used, as all women were assigned a unique study number. The findings of the study were shared with hospital management in a dissemination meeting held after the study. Study identification numbers of participants that were seropositive to T. gondii antibodies were referred to routine antenatal care management through the attending clinician who had a register with patient identifiers that were blinded to the investigators.

Patient and public involvement

There was no direct patient and public involvement. The findings from this study were shared with Namwala Hospital Management.

Results

The study enrolled 401 pregnant women with a median age of 27 (IQR: 24–30) years. Table 1 shows details of the cross-tabulation of sociodemographic characteristics and toxoplasmosis detection rate. The largest proportion, 223 (55.6%), attained a primary level of education, 308 (76.8%) were farmers, and 160 (40.4%) resided in other areas (Banamwanze, Banga, Chaako, Chibunze, Chinyemu, Cooperative, Council compound, Kaambwe, Kaliweza). In addition, most women (327, 81.6%) were married, 256 (63.8%) had one child and 355 (88.5%) received Intermittent Preventive Treatment of Malaria for Pregnant Women. Close to two-thirds (250, 62.3%) of the participants were in their second trimester (table 1).

Table 1. Toxoplasma seropositivity to IgG and/or IgM and sociodemographic characteristics n=401.

Variable Total populationN(%) Toxoplasmosis status IgG and/or IgM P value
Negative n, (%) Positive n (%)
Demographic characteristics
Age median (IQR) 27(24-30) 27(24-30) 26(21-31)
Gestational age median (IQR) 26(22-28) 26(22-28) 26.5 (24–28)
Education 0.079
Primary 223 (55.6) 211 (55.3) 12 (63.2)
Secondary 12 (3.0) 12 (3.1) 0 (0.0)
Tertiary 10 (2.5) 8 (2.1) 2 (10.5)
None 156 (38.9) 151 (39.5) 5 (26.3)
Occupation 0.433
Other* 93 (23.2) 90 (23.6) 3 (15.8)
Farmer 308 (76.8) 292 (76.4) 16 (84.2)
Residence 0.623
Belina 87 (21.7) 83 (21.7) 4 (21.1)
Chikwata 23 (5.7) 23 (6.0)
Kalundu 30 (7.5) 33 (8.6) 2 (10.5)
Location area 28 (7.0) 25 (6.5) 3 (15.8)
Maunga 66 (16.5) 63 (16.6) 3 (15.8)
Other 162 (40.4) 155 (40.6) 7 (36.8)
Marital status 0.759
Married 327 (81.6) 311 (81.4) 16 (84.2)
Unmarried 74 (18.5) 71 (18.6) 3 (15.8)
Parity 6 (31.5) 0.045
No child 52 (13.0) 46 (12.0)
One child 256 (63.8) 247 (64.7) 9 (47.4)
Two and above 93 (23.2) 89 (23.3) 4 (21.1)
Have you taken IPTp—sulphadoxine pyrimethamine? 0.005
No 46 (11.5) 40 (10.5) 6 (31.6)
Yes 355 (88.5) 342 (89.5) 13 (68.4)
Trimester 0.757
1 6 (1.5) 6 (1.6) 0 (0)
2 250 (62.3) 239 (62.6) 11 (57.9)
3 145 (36.2) 137 (35.8) 8 (42.1)
*

(Unemployed, Trader, Gardner, Housewife, Maid, Nurse, Policewoman, Teacher).

(Banamwanze, Banga, Chaako, Chibunze, Chinyemu, Cooperative, Council compound, Kaambwe, Kaliweza).

IPTpIntermittent Preventive Treatment of Malaria for Pregnant WomenIQRinterquartile range

Of the 401 pregnant women, 19 (4.7%, 95% CI: 2.9 to 7.3) were positive for Toxoplasma antibodies, 0.7% (n=3) were seropositive for IgM and 4.2% (n=17) were seropositive for IgG, while one of the participants was seropositive for both IgG and IgM. Among those that were seropositive to Toxoplasma IgG antibodies, only one had a gestational age of less than 20 weeks.

Slightly above half, 225 (56.1%) owned a cat, and 223 (55.6%) regularly cleaned cat litter. Nearly everyone, 378 (94.3%), drank unpasteurised milk, 392 (97.8%) were in regular contact with soil, 384 (95.8%) handled manure and 367 (91.5%) did not boil drinking water (table 2). All respondents declined eating undercooked or uncooked meat and eating uncooked or undercooked vegetables.

Table 2. Toxoplasma seropositivity by risk factors n=401.

Variable TotalN(%) Toxoplasmosis status IgG and/or IgM P value
Negative N,(%) Positive N(%)
Risk Factors to toxoplasmosis
Do you keep a cat? 0.219
No 176 (43.9) 170 (44.5) 6 (31.6)
 Yes 225 (56.1) 212 (55.5) 13 (68.4)
Do you clean cat litter? 0.204
No 178 (44.4) 172 (45.0) 6 (31.6)
 Yes 223 (55.6) 210 (55.0) 13 (68.24)
Do you drink unpasteurised milk? 0.299
No 378 (94.3) 359 (94.0) 19(100)
 Yes 23 (5.7) 23 (6.0)
Are you in regular contact with soil such as farming? 0.241
No 8 (2.0) 7 (1.8) 1 (5.3)
 Yes 393 (98.0) 375 (98.2) 18 (94.7)
Do you handle manure? 0.731
No 17 (4.2) 16 (4.2) 1 (5.3)
 Yes 384 (95.8) 366 (95.8) 18 (94.7)
Do you boil water before drinking? 0.166
No 367 (91.5) 351 (91.9) 16 (84.2)
 Yes 34 (8.5) 31 (8.1) 3 (15.8)

None of the factors that were included in the multivariate were significant as the model was not significant. Table 3 shows the risk factors for Toxoplasma IgG/IgM seropositivity.

Table 3. Risk factors for Toxoplasma IgG/IgM seropositivity.

Covariate N aOR (95% CI) P value
Contact with soil
 No 8 Ref Ref
 Yes 393 4.323 (0.458 to 40.794) 0.201
Boiling water
 No 367 Ref Ref
 Yes 34 0.987 (0.171 to 5.687) 0.989
Education
Education—uneducated 156 Ref Ref
Education—primary 223 0.422 (0.137 to 1.303) 0.134
Education—secondary 12 29249032.06 (0.000 -) 0.999
Education—tertiary 10 0.119 (0.013 to 1.128) 0.064
Parity
Parity no child 52 Ref Ref
Parity one child 256 4.468 (1.332 to 14.992) 0.015
Parity two or more children 93 3.714 (0.887 to 15.559) 0.073

Discussion

This study is the second study to investigate the seroprevalence and associated risk factors in pregnant women in Zambia and the first in a rural setting such as Namwala. The only previous study was conducted at the University Teaching Hospital, the capital city of Zambia.16 T. gondii remains a disease with wide distribution globally with a heterogeneous reach across and within countries.28

This study found a seroprevalence of 0.7% for Toxoplasma IgM and 4% for Toxoplasma IgG, and an overall Toxoplasma seroprevalence of 4.7% (95% CI: 2.9 to 7.3) in pregnant women in the Namwala district of Zambia, presenting a low endemic picture. The overall seroprevalence is consistent with that reported in in a previous study in Zambia with an overall seroprevalence of 5.87% (95% CI: 3.8 to 8.6).16 29 Studies in Portugal and Ethiopia have reported higher levels of overall Toxoplasma seroprevalence of 24.4% and 81.8, respectively.30 31 The presence of IgM antibodies has been associated with poor birth outcomes with IgM appearing first and then receding with IgG becoming more predominant.32 33 The low prevalence of Toxoplasma IgM is in agreement with those previously reported from Iran and Egypt, which found an IgM seroprevalence of 1.3% and 0.5, respectively.34 35 This could suggest a lower risk of unwanted birth outcomes to Toxoplasma infection in this population. In contrast to our study, several studies have reported an absence of Toxoplasma IgM in pregnant women in Mexico, Tanzania, Ghana and Zambia.1216 36,38 Toxoplasma IgM seroprevalences higher than those in our study have been reported in several studies, ranging from 2.8% in Columbia to 6.3% in India.239,43 These differences could be driven by inherent differences in the drivers of infection, such as high consumption of uncooked meat, cat ownership and varying ecosystems and cultures in different countries and areas.44 Additionally, the multiplicity of laboratory methods employed by different studies could also account for the differences, as some studies used ELISA methods, while others used immunochromatographic tests and microparticle immunoassays. We reported a seroprevalence of 4% for Toxoplasma IgG in the current study. This is comparable to the Toxoplasma IgG prevalence reported in South Korea of 4%45 and Mexico of 4.2%.38 Slightly higher Toxoplasma IgG estimates were seen in Zambia (5.9%) and Mexico (6.1%).12 16 In contrast, much higher seroprevelances ranging from 25% to 74.9% have been reported among pregnant women worldwide.3134 36 37 41 43 46,48 These differences could be due to variations in ecologies that drive infection and lower infection rates, sparse population geographies that offer little opportunity for an infection encounter and possible clustering of cases in areas not yet investigated.

None of the risk factors included in our study significantly explained the seroprevalence of toxoplasmosis in our study.

Our findings cannot be deemed representative of other populations in Zambia and must not be generalised as such. The study initially proposed to investigate the seroprevelance of toxoplasmosis in Namwala, Nyimba and Ndola districts but was limited due to resources and travel restrictions as data collection was conducted at the height of the COVID-19 pandemic. Despite this, our study presents important findings in a rural Toxoplasma-susceptible population in Zambia with implications for mitigation using the one-health approach. Our findings must be interpreted with caution as we could not conclusively confirm active infections to augment the findings from the IgG and IgM assays through the use the Avidity assay. Additionally, the OnSite Rapid Diagnostic test has been reported to have low specificity in some populations, which could have a bearing on our findings.

Conclusions

We found a low seroprevalence of T. gondii infection in pregnant women in the Namwala District of Southern Zambia at 4.7%. We recommend deliberate health education in Toxoplasma preventive practices to pregnant women during their first antenatal visit to avoid possible primary infection during pregnancy. Screening for T. gondii infection may not be warranted due to the low prevalence observed in this population. We recommend more research to understand the epidemiology of T. gondii infection across Zambia.

supplementary material

online supplemental file 1
bmjopen-14-6-s001.pdf (784.1KB, pdf)
DOI: 10.1136/bmjopen-2024-084582
online supplemental file 2
bmjopen-14-6-s002.pdf (625.5KB, pdf)
DOI: 10.1136/bmjopen-2024-084582
online supplemental file 3
bmjopen-14-6-s003.pdf (207.7KB, pdf)
DOI: 10.1136/bmjopen-2024-084582
online supplemental file 4
bmjopen-14-6-s004.pdf (744KB, pdf)
DOI: 10.1136/bmjopen-2024-084582

Acknowledgements

The authors would like to acknowledge the technical support provided by Mr. Ladislav Moonga. We would like to thank the management and staff from the Biomedical Sciences Department at the TDRC and Namwala District Hospital laboratory where the sample processing and analysis was performed. Our thanks are also extended to the African Centre for Infectious Disease Research in Humans and Animals who supported the initial field work for the study and for supporting this work that was carried out as part of PhD work for VD. Lastly, the authors would like to thank the study participants with whom this study would have not been possible.

Footnotes

Funding: The study received support for field work from the African Centre for Infectious Disease Research in Humans and Animals (grant number not applicable), and VD was supported for his academic passage. No further funding was obtained.

prepub: Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2024-084582).

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Consent obtained directly from patient(s).

Ethics approval: This study involved human participants and was approved by Tropical Diseases Research Centre Institutional Review Board (Institutional Review Board Number 00002911). Participants gave informed consent to participate in the study before taking part.

Map disclaimer: The inclusion of any map (including the depiction of any boundaries therein) or of any geographic or locational reference does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

Patient and public involvement: Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

Contributor Information

Victor Daka, Email: dakavictorm@gmail.com.

Moses Mukosha, Email: mmukosha@gmail.com.

Sharon D Zimba, Email: sharonduba@gmail.com.

Andrew M Phiri, Email: andrew.phiri@unza.zm.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

References

  • 1.Robert-Gangneux F, Toxoplasmosis DS, Can Fam Physician It is not only the cat that did it: how to prevent and treat congenital Toxoplasmosis. J Infect. 2014;68:S125–33. doi: 10.1016/j.jinf.2013.09.023. [DOI] [PubMed] [Google Scholar]
  • 2.Ullah A, Bibi Y, Mohammad S, et al. Prevalence of Toxoplasmosis in pregnant women. PJMHS . 2022;16:857–9. doi: 10.53350/pjmhs22166857. [DOI] [Google Scholar]
  • 3.Kalani H, Mohammadi F, Faridnia R, et al. Seroprevalence of Toxoplasmosis in Kermanshah city, West of Iran. Ann Parasitol. 2021;67:229–36. doi: 10.17420/ap6702.333. [DOI] [PubMed] [Google Scholar]
  • 4.Smit GSA, Vu BTL, Do DT, et al. Sero-Epidemiological status and risk factors of Toxoplasmosis in pregnant women in northern Vietnam. BMC Infect Dis . 2019;19:329. doi: 10.1186/s12879-019-3885-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Torgerson PR, Mastroiacovo P. The global burden of congenital Toxoplasmosis: a systematic review. Bull World Health Organ. 2013;91:501–8. doi: 10.2471/BLT.12.111732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rostami A, Riahi SM, Gamble HR, et al. Global prevalence of latent Toxoplasmosis in pregnant women: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26:673–83. doi: 10.1016/j.cmi.2020.01.008. [DOI] [PubMed] [Google Scholar]
  • 7.Adugna B, Tarekegn ZS, Damtie D, et al. Seroepidemiology of Toxoplasma Gondii among pregnant women attending Antenatal care in Northwest Ethiopia. Infect Drug Resist . 2021;14:1295–303. doi: 10.2147/IDR.S299106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Babaie J, Amiri S, Mostafavi E, et al. Seroprevalence and risk factors for Toxoplasma Gondii infection among pregnant women in northeast Iran. Clin Vaccine Immunol. 2013;20:1771–3. doi: 10.1128/CVI.00125-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Karimi G, Mardan A, Zadsar M. Toxoplasma and blood transfusion. Iran J Parasitol. 2014;9:597–8. [PMC free article] [PubMed] [Google Scholar]
  • 10.Wang ZD, Wang SC, Liu HH, et al. Prevalence and burden of Toxoplasma Gondii infection in HIV-infected people: a systematic review and meta-analysis. Lancet HIV. 2017;4:e177–88. doi: 10.1016/S2352-3018(17)30005-X. [DOI] [PubMed] [Google Scholar]
  • 11.Bollani L, Auriti C, Achille C, et al. Congenital Toxoplasmosis: the state of the art. Front Pediatr. 2022;10:894573. doi: 10.3389/fped.2022.894573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Alvarado-Esquivel C, Sifuentes-Alvarez A, Narro-Duarte SG, et al. Seroepidemiology of Toxoplasma Gondii infection in pregnant women in a public hospital in northern Mexico. BMC Infect Dis. 2006;6:113. doi: 10.1186/1471-2334-6-113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Peyron F, Mc Leod R, Ajzenberg D, et al. Congenital Toxoplasmosis in France and the United States: one parasite. PLoS Negl Trop Dis . 2017;11:e0005222. doi: 10.1371/journal.pntd.0005222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Havelaar AH, Kemmeren JM, Kortbeek LM. Disease burden of congenital Toxoplasmosis. Clin Infect Dis. 2007;44:1467–74. doi: 10.1086/517511. [DOI] [PubMed] [Google Scholar]
  • 15.Valentini P, Buonsenso D, Barone G, et al. Spiramycin/Cotrimoxazole versus Pyrimethamine/Sulfonamide and Spiramycin alone for the treatment of Toxoplasmosis in pregnancy. J Perinatol. 2015;35:90–4. doi: 10.1038/jp.2014.161. [DOI] [PubMed] [Google Scholar]
  • 16.Frimpong C, Makasa M, Sitali L, et al. Seroprevalence and determinants of Toxoplasmosis in pregnant women attending Antenatal clinic at the University teaching hospital, Lusaka, Zambia. BMC Infect Dis. 2017;17:10. doi: 10.1186/s12879-016-2133-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Marques J, da Silva D, Correia N, et al. Prevalence and risk factors for human Toxoplasmosis in a rural community. J Venom Anim Toxins Incl Trop Dis. 2008;14:673–84. doi: 10.1590/S1678-91992008000400010. [DOI] [Google Scholar]
  • 18.Dubey JP, Vianna MCB, Sousa S, et al. Characterization of Toxoplasma Gondii isolates in free-range chickens from Portugal. J Parasitol. 2006;92:184–6. doi: 10.1645/GE-652R.1. [DOI] [PubMed] [Google Scholar]
  • 19.Malama S, Johansen TB, Muma JB, et al. Characterization of Mycobacterium Bovis from humans and cattle in Namwala district, Zambia. Vet Med Int. 2014;2014:187842. doi: 10.1155/2014/187842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Monde N, Munyeme M, Muwonge A, et al. Characterization of non-tuberculous Mycobacterium from humans and water in an Agropastoral area in Zambia. BMC Infect Dis. 2018;18:20. doi: 10.1186/s12879-017-2939-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol from Bed to Bench. 2013;6:14–7. [PMC free article] [PubMed] [Google Scholar]
  • 22.Vueba AN, Faria CP, Almendra R, et al. Serological prevalence of Toxoplasmosis in pregnant women in Luanda (Angola): Geospatial distribution and its association with socio-demographic and clinical-obstetric determinants. PLoS One. 2020;15:e0241908. doi: 10.1371/journal.pone.0241908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Onduru OG, Aboud S. Prevalence and risk factors for typical signs and symptoms of Toxoplasmosis in children born to at risk pregnant women attending prenatal care in Temeke district, Tanzania. Scientific African . 2021;11:e00690. doi: 10.1016/j.sciaf.2020.e00690. [DOI] [Google Scholar]
  • 24.Gontijo da Silva M, Clare Vinaud M, de Castro AM. Prevalence of Toxoplasmosis in pregnant women and vertical transmission of Toxoplasma Gondii in patients from basic units of health from Gurupi. PLoS ONE . 2012;10:e0141700. doi: 10.1371/journal.pone.0141700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Taber KS. The use of Cronbach’s alpha when developing and reporting research instruments in science education. Res Sci Educ. 2018;48:1273–96. doi: 10.1007/s11165-016-9602-2. [DOI] [Google Scholar]
  • 26.Gomez CA, Budvytyte LN, Press C, et al. Evaluation of three point-of-care tests for detection of Toxoplasma immunoglobulin IgG and Igm in the United States: proof of concept and challenges. Open Forum Infect Dis. 2018;5:ofy215. doi: 10.1093/ofid/ofy215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wassef R, Abdel-Malek R. Validity of a new Immunochromatographic test in detection of Toxoplasma Gondii in cancer patients. J Parasit Dis. 2019;43:83–6. doi: 10.1007/s12639-018-1063-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Montazeri M, Mikaeili Galeh T, Moosazadeh M, et al. The global serological prevalence of toxoplasma gondii in felids during the last five decades (1967–2017): a systematic review and meta-analysis. Parasites Vectors . 2020;13:82. doi: 10.1186/s13071-020-3954-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Andiappan H, Nissapatorn V, Sawangjaroen N, et al. Toxoplasma infection in pregnant women: A current status in Songklanagarind hospital, Southern Thailand. Parasit Vectors. 2014;7:239. doi: 10.1186/1756-3305-7-239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fenta DA. Seroprevalence of Toxoplasma Gondii among pregnant women attending Antenatal clinics at Hawassa University comprehensive specialized and Yirgalem general hospitals, in Southern Ethiopia. BMC Infect Dis. 2019;19:1056. doi: 10.1186/s12879-019-4694-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lopes AP, Dubey JP, Moutinho O, et al. Seroepidemiology of Toxoplasma Gondii infection in women from the north of Portugal in their childbearing years. Epidemiol Infect. 2012;140:872–7. doi: 10.1017/S0950268811001658. [DOI] [PubMed] [Google Scholar]
  • 32.Nadia NAC, Nino LG, Cédric Y, et al. Seroprevalence of Toxoplasma Gondii IgG and Igm antibodies and associated risk factors among pregnant women consulted in three health centers in Dschang, Cameroon. Parasite Epidemiol Control. 2023;22:e00306. doi: 10.1016/j.parepi.2023.e00306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhang Y, Song R. Investigation on pregnancy outcomes and risk factors in pregnant women infected with Toxoplasma Gondii. Chinese. 2014;22:221–3. [PubMed] [Google Scholar]
  • 34.Bassiony H, Soliman N, Tawab S, et al. Sero-prevalence and risk factors associated with Toxoplasma Gondii infection among pregnant women in Alexandria. Int J Reprod Contracept Obstet Gynecol . 2016:4220–7. doi: 10.18203/2320-1770.ijrcog20164318. [DOI] [Google Scholar]
  • 35.Yad Yad MJ, Jomehzadeh N, Jafar Sameri M, et al. Seroprevalence of anti-Toxoplasma Gondii antibodies among pregnant woman in South Khuzestan, Iran. Jundishapur J Microbiol. 2014;7:e9998. doi: 10.5812/jjm.9998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ayi I, Sowah AOK, Blay EA, et al. Toxoplasma Gondii infections among pregnant women, children and HIV-Seropositive persons in Accra, Ghana. Trop Med Health. 2016;44:17. doi: 10.1186/s41182-016-0018-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mwambe B, Mshana SE, Kidenya BR, et al. Sero-prevalence and factors associated with Toxoplasma Gondii infection among pregnant women attending Antenatal care in Mwanza, Tanzania. Parasit Vectors. 2013;6:222. doi: 10.1186/1756-3305-6-222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sandoval-Carrillo AA, Vértiz-Hernández AA, Salas-Pacheco JM, et al. Toxoplasma Gondii infection in pregnant women: a cross-sectional study in Matehuala city, Mexico. BMJ Open. 2020;10:e033995. doi: 10.1136/bmjopen-2019-033995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Julius Okojokwu O, Esther Nwachukwu E, Ahmed Ali M, et al. Seroprevalence of anti-Toxoplasma IgG and Igm among pregnant women attending Antenatal clinic in JOS-North, plateau state, Nigeria. Microbes Infect Dis. 2023;4:285–95. [Google Scholar]
  • 40.Singh B, Debrah LB, Acheampong G, et al. Seroprevalence and risk factors of Toxoplasma Gondii infection among pregnant women in Kumasi: A cross-sectional study at a district-level hospital, Ghana. Infect Dis Obstet Gynecol. 2021;2021:6670219. doi: 10.1155/2021/6670219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Rosso F, Les JT, Agudelo A, et al. Prevalence of infection with Toxoplasma Gondii among pregnant women in CALI, Colombia, South America. Am J Trop Med Hyg. 2008;78:504–8. [PubMed] [Google Scholar]
  • 42.Vaz RS, Thomaz-Soccol V, Sumikawa E, et al. Serological prevalence of Toxoplasma Gondii antibodies in pregnant women from Southern Brazil. Parasitol Res. 2010;106:661–5. doi: 10.1007/s00436-009-1716-2. [DOI] [PubMed] [Google Scholar]
  • 43.Ahmadpour GR, Ezatpour B, Hadighi R, et al. Seroepidemiology of Toxoplasma Gondii infection in pregnant women in West Iran: determined by ELISA and PCR analysis. J Parasit Dis . 2017;41:237–42. doi: 10.1007/s12639-016-0784-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for Toxoplasmosis. Clin Microbiol Rev. 2012;25:264–96. doi: 10.1128/CMR.05013-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Han K, Shin DW, Lee TY, et al. Seroprevalence of Toxoplasma Gondii infection and risk factors associated with Seropositivity of pregnant women in Korea. J Parasitol. 2008;94:963–5. doi: 10.1645/GE-1435.1. [DOI] [PubMed] [Google Scholar]
  • 46.Dawet A, Yusuf K, Golnaan C, et al. Sero-prevalence of Toxoplasma Gondii in pregnant women attending ante natal care in JOS University teaching hospital (JUTH) J Infect Dis Epidemiol . 2022;8:285. doi: 10.23937/2474-3658/1510285. [DOI] [Google Scholar]
  • 47.Singh S, Munawwar A, Rao S, et al. Serologic prevalence of Toxoplasma Gondii in Indian women of child bearing age and effects of social and environmental factors. PLoS Negl Trop Dis. 2014;8:e2737. doi: 10.1371/journal.pntd.0002737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Al-Adhroey AH, Mehrass AA-KO, Al-Shammakh AA, et al. Prevalence and predictors of Toxoplasma Gondii infection in pregnant women from Dhamar, Yemen. BMC Infect Dis. 2019;19:1089. doi: 10.1186/s12879-019-4718-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    online supplemental file 1
    bmjopen-14-6-s001.pdf (784.1KB, pdf)
    DOI: 10.1136/bmjopen-2024-084582
    online supplemental file 2
    bmjopen-14-6-s002.pdf (625.5KB, pdf)
    DOI: 10.1136/bmjopen-2024-084582
    online supplemental file 3
    bmjopen-14-6-s003.pdf (207.7KB, pdf)
    DOI: 10.1136/bmjopen-2024-084582
    online supplemental file 4
    bmjopen-14-6-s004.pdf (744KB, pdf)
    DOI: 10.1136/bmjopen-2024-084582

    Data Availability Statement

    All data relevant to the study are included in the article or uploaded as supplementary information.


    Articles from BMJ Open are provided here courtesy of BMJ Publishing Group

    RESOURCES